0001209191-21-067150.txt : 20211130
0001209191-21-067150.hdr.sgml : 20211130
20211130165753
ACCESSION NUMBER: 0001209191-21-067150
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211126
FILED AS OF DATE: 20211130
DATE AS OF CHANGE: 20211130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BIOVENTURES 2018, L.P.
CENTRAL INDEX KEY: 0001729505
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211460248
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2018 LLC
CENTRAL INDEX KEY: 0001818702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211460247
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9206
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2018 GP LLC
CENTRAL INDEX KEY: 0001818701
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 211460246
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9206
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-26
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001729505
MPM BIOVENTURES 2018, L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001818702
MPM BioVentures 2018 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001818701
MPM BioVentures 2018 GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2021-11-26
4
S
0
6545
35.49
D
3035320
I
See Footnote
Common Stock
2021-11-26
4
S
0
6129
36.03
D
3029191
I
See Footnote
Common Stock
2021-11-29
4
S
0
10073
34.46
D
3019118
I
See Footnote
Common Stock
2021-11-29
4
S
0
298
35.37
D
3018820
I
See Footnote
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
The shares were sold as follows: 3,899 by MPM BioVentures 2014, L.P. ("BV 2014"), 134 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,463 by MPM BioVentures 2018, L.P. ("BV 2018") and 49 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.915 to $35.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,721,258 by BV 2014, 97,289 by, 59,245 by AM BV2014, 1,087,109 by BV 2018, 48,966 by BV 2018(B) and 21,453 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018 and 45 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B) and 21,408 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by BV 2018 and 75 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B) and 21,333 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 178 by BV 2014, 6 by AM BV2014, 112 by BV 2018 and 2 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.125 to $35.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B) and 21,331 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P.
2021-11-30
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC
2021-11-30
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC
2021-11-30